Cubist files INDs for infection treatments

By Mass High Tech staff

Cubist starts in-human tests of bacterial infection drug [February 17, 2009]

Alnylam could get $102M from Cubist RNAi development deal [January 9, 2009]

Cubist nearly doubles quarterly revenue in a year [October 17, 2008]

Cubist expands lab research facility [September 30, 2008]

Lexington-based Cubist Pharmaceuticals Inc. announced it has filed two Investigational New Drug applications with the U.S. Food and Drug Administration.

The INDs include CB-182,804, Cubist’s drug treatment of multi-drug resistant Gram-negative infections, and the CB-183,315, for treatment of Clostridium difficile associated diarrhea (CDAD).

If not addressed, Gram-negative infections can lead to pneumonia, blood stream infections, urinary tract infections and intra-abdominal infections. And Cubist (Nasdaq:CBST) officials said CDAD cases are on the rise because of a new strain of Clostridium difficile.

Cubist reported a 45 percent jump in third quarter 2008 revenue over the same period the previous year. Cubist had $76.3 million in Q3 2007 compared with $110.6 million in 2008.

In September, Cubist opened a 35,000-square-foot research facility at the company’s headquarters in Lexington. The facility, constructed of environmentally friendly materials, adds enough lab space to fit an additional 100 people, officials said.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.